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The cytokine thymic stromal lymphopoietin (TSLP) has recently been implicated in the 
pathogenesis of atopic dermatitis (AD) and other allergic diseases in humans. To further 
characterize its role in this disease process, transgenic mice were generated that express a 
keratinocyte-specific, tetracycline-inducible TSLP transgene. Skin-specific overexpression of 
TSLP resulted in an AD-like phenotype, with the development of eczematous lesions 
containing inflammatory dermal cellular infiltrates, a dramatic increase in Th2 CD4
 
 
 
 T cells 
expressing cutaneous homing receptors, and elevated serum levels of IgE. These transgenic 
mice demonstrate that TSLP can initiate a cascade of allergic inflammation in the skin and 
provide a valuable animal model for future study of this common disease.
 
Atopic dermatitis (AD) is a common allergic
inflammatory disease of the skin that is character-
ized by intense pruritus and chronic eczematous
plaques and is often associated with a personal
or family history of allergic disease (1, 2). In
addition, it is the most common chronic skin
disease in childhood, affecting an estimated
7–12% of school-aged children (3). Although
most cases are mild and usually clear up, some
patients experience severe or widespread disease
that can be physically, socially, and/or emotion-
ally debilitating (4). Although the underlying
cause of AD remains unclear, its pathogenesis
is thought to involve a Th2 cell–mediated
allergic inflammatory cascade (5, 6). This type
of inflammation is characterized by the pro-
duction of proallergic cytokines (IL-4, IL-5,
IL-13, and TNF-
 
 
 
) by CD4
 
 
 
 T cells, leading
to elevated levels of IgE and leukocytic infil-
tration of the dermis (6, 7). Local DCs are
thought to play a crucial role in this process
by polarizing naive CD4
 
 
 
 T cells to differen-
tiate into Th2 lymphocytes. However, the
initiating factors that influence these impor-
tant antigen-presenting cells to instruct T
helper cell polarization toward this proallergic
phenotype remain unknown.
One candidate factor for the local activation
of skin DCs during allergic inflammation is the
cytokine thymic stromal lymphopoietin (TSLP).
TSLP is expressed primarily by epithelial cells,
including keratinocytes, whereas the TSLP re-
ceptor is expressed by hematopoietic cells, in-
cluding monocytes and CD11c
 
 
 
 DCs (8–10).
In vitro, human TSLP can activate CD11c
 
 
 
DCs and induce their production of the Th2
cell–attracting chemokines CCL17 and CCL22
(9). Moreover, naive CD4
 
 
 
 T cells, primed by
TSLP-treated DCs, underwent extensive pro-
liferation and differentiation into Th2 lympho-
cytes on restimulation, with the production of
IL-4, IL-5, IL-13, and TNF-
 
 
 
 (11). Addition-
ally, TSLP is highly expressed by keratinocytes
in acute and chronic lesions of AD, where it is
associated with the activation and migration of
DCs within the dermis (11). These data support
a role for TSLP as one of the initiating factors
in AD, responsible for activating cutaneous
DCs and endowing them with the ability to
polarize CD4
 
 
 
 T cells toward a Th2 cell allergic
response.
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Based on these data, we hypothesized that targeted ex-
pression of TSLP to the skin of transgenic mice would result
in an AD-like phenotype. We report that mice expressing an
inducible, epidermal-specific TSLP transgene demonstrate
clinical, histologic, cellular, and biochemical characteristics
that closely resemble those of human AD. These include
dermal infiltrates containing lymphocytes, mast cells, and eo-
sinophils, an increase in Th2 cytokines in the effected skin,
and elevated circulating levels of IgE. Disease is associated
with a dramatic increase in IL-4–producing CD4
 
 
 
 T cells,
which also express CCR4 and other skin homing receptors,
in both the skin-draining LNs and the spleen. Consistent
with the hypothesis that TSLP can act directly on myeloid
cells, transgenic mice lacking T cells still develop disease.
Collectively, these mice directly demonstrate that TSLP can
initiate an AD-like allergic inflammation on transgenic ex-
pression in the skin.
 
RESULTS
Skin-specific expression of TSLP results in moderate 
to severe dermatitis
 
Mice containing a tetracycline-inducible, skin-specific TSLP
transgene were generated by crossing tetO-TSLP mice with
mice expressing the reverse tetracycline transactivator in the
skin under control of the keratin 5 promoter (K5-rtTA mice;
reference 12). Animals carrying both transgenes (referred to
as K5-TSLP mice), along with nontransgenic littermates,
were started on dietary doxycycline (dox) at approximately 5
wk of age. Skin-targeted transgene expression in K5-TSLP
mice was confirmed by RT-PCR (Fig. 1 A). In addition, ex-
pression of TSLP directly in the skin from K5-TSLP and
control mice was examined. As shown in Fig. 1 B, TSLP ex-
pression was evident in the epidermis of K5-TSLP mice,
whereas only scattered cells expressed TSLP in the skin from
control mice. dox-treated mice carrying single transgenes, as
well as untreated K5-TSLP mice, were also examined and
were indistinguishable from nontransgenic littermates with
respect to all parameters studied (unpublished data).
K5-TSLP mice developed skin disease beginning at 
 
 
 
2–3
wk of dox treatment. Their lesions consisted of mild ery-
thema at 2 wk with progression to obvious eczematous-like
changes, including erythema, crusting, and erosions, by 3–4
wk (Fig. 1 C). Lesions were most common on the snout,
postauricular region, nape of the neck, and upper back. Less
commonly, lesions were found on the anterior neck and
hind legs. The majority of mice exhibited a mild xerosis that
was generalized, and conjunctivitis was observed in a few
cases (not depicted). Together, these clinical features closely
resemble those observed during human AD. In addition to
the exterior manifestations of disease, these mice also dis-
played pronounced splenomegaly and lymphadenopathy
(unpublished data).
Eczematous skin samples from K5-TSLP mice were sub-
jected to histological examination and compared with skin
from nontransgenic littermates (Fig. 2). By 5 wk of dox
treatment, lesional skin from K5-TSLP mice demonstrated
all of the characteristic changes of eczematous inflammation
observed in human AD, including acanthosis (epidermal hy-
pertrophy), spongiosis (interepidermal edema), hyperkerato-
sis (thickening of the stratum corneum), and a dermal mono-
nuclear cell infiltrate. These features were not present in
either clinically normal K5-TSLP skin or nontransgenic skin.
A more detailed examination of the inflammatory infiltrate
revealed, in addition to a predominance of lymphocytes and
macrophages, an abundance of mast cells and eosinophils. In
contrast to the other, nonspecific changes observed, the
presence of these latter cell types is highly suggestive of an
allergic inflammatory process.
To further investigate the nature of the inflammation
seen in the skin of K5-TSLP mice, skin sections were stained
with BM8, an antibody that recognizes activated macro-
phages and Langerhans cells in the skin. Skin sections from
K5-TSLP mice showed extensive accumulation of BM8
 
 
 
cells, with only scattered cells staining in control skin. Inter-
estingly, the staining was restricted to the dermis, with little
Figure 1. Skin-targeted transgenic expression of TSLP causes 
eczematous-like skin lesions accompanied by pronounced lymphade-
nopathy and splenomegaly. (A) RT-PCR analysis of TSLP transgene 
expression in the skin of a K5-TSLP mouse and a normal littermate control 
(NLC) after 3 wk of dox treatment. From the K5-TSLP mouse, total RNA 
isolated from affected lesional skin (L) and unaffected skin (U) were ana-
lyzed separately. (B) An immunohistochemical localization of TSLP in the 
skin of a K5-TSLP mouse as compared with NLC. TSLP in a K5-TSLP mouse 
was expressed in the epidermis and its basement membrane (brown). 
(C) Images showing a K5-TSLP mouse and NLC after 3 wk of dox treatment. 
Arrowheads mark eczematous lesions on the snout and trunk. Images are 
representative of  10 K5-TSLP mice analyzed. 
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or no staining of cells in the epidermis (Fig. 3). These data
are consistent with the presence of an inflammatory infil-
trate, containing activated macrophages, mast cells, and eo-
sinophils, in the dermis of K5-TSLP mice. We also observed
increased expression of CD31 on endothelial cells in the der-
mis from affected K5-TSLP skin, which was consistent with
an inflammatory response (unpublished data).
 
Cellular and hematological analyses of K5-TSLP mice reveal 
a Th2 inflammatory response targeted to the skin
 
AD and the other allergic diseases are generally characterized
by dysregulated Th2 lymphocyte activation, IgE overpro-
duction, activation of mast cells, and eosinophilia. K5-TSLP
mice displayed pronounced splenomegaly and lymphade-
nopathy in both cutaneous and noncutaneous LNs (unpub-
lished data). Moreover, consistent with the proposed func-
tion of TSLP in the differentiation of Th2 cells, intracellular
cytokine analysis revealed a dramatic increase in the fre-
quency of IL-4–producing CD4
 
 
 
 T cells in both the spleens
and LNs of K5-TSLP mice (Fig. 4 A and Table I). Many of
these IL-4–producing cells coexpressed IL-10 or TNF-
 
 
 
;
however, there was little or no increase in the frequency of
IFN-
 
 
 
–producing cells. RT-PCR from erythematous skin
of K5-TSLP mice confirmed this Th2 cell profile, with an
increase in the proallergic cytokines IL-4, IL-5, and TNF-
 
 
 
and undetectable IFN-
 
 
 
 (Fig. 4 B). Consistent with this Th2
response, analysis of serum immunoglobulins showed in-
creases in both IgG1 and IgE, along with a decrease in IgG2a
in K5-TSLP mice (Table II).
Compared with controls, there was a 14-fold increase in
IL-4–producing cells in the skin-draining LNs and an 18-
fold increase in the spleen, but just a 4-fold increase in the
intestinal mesenteric LNs (Table I). In addition, histological
analysis of hematoxylin and eosin (H&E)–stained sections of
both the small intestine and colon from K5-TSLP mice
showed no inflammation in these tissues (unpublished data).
These results highlight the organ specificity of the disease
phenotype, which may in part be mediated by selective mi-
gration of the responding Th2 CD4
 
 
 
 T cells to the skin.
Homing to the inflamed skin requires expression of ligands
for either P- or E-selectin (referred to as P- or E-ligand) and
is associated with expression of CCR4 and CCR10, which
are receptors for the cutaneous chemokines CCL17 and
CCL27 (13–15). CCR4 is also expressed by nearly all of the
IL-4–producing Th2 cells (16, 17). Based on these expres-
sion patterns, we hypothesized that these molecules may play
important roles in the tissue- and Th2 cell–specific inflam-
mation observed in K5-TSLP mice.
Using P- and E-selectin fusion proteins, CD4
 
 
 
 T cells
from the spleen and subcutaneous-draining LNs of K5-
TSLP mice were examined for P- and E-ligand expression.
In both tissues, there was a striking increase in the expression
of both P- and E-ligand among the total CD4
 
 
 
 T cell popu-
lation (Fig. 5 A). Moreover, these P- and E-ligand–express-
ing cells were dramatically enriched in IL-4 producers, dem-
onstrating a direct correlation between Th2 effector cell
function and expression of cutaneous homing receptors in
the K5-TSLP animals.
Figure 2. Histological observations of the skin in K5-TSLP mice. 
Paraffin-embedded sections of lesional skin from a K5-TSLP mouse and an 
NLC were stained with H&E. (A) Skin sections showing pronounced acanthosis 
(arrow) and dermal infiltration (arrowhead) at 10 . (B) Images of lesional 
skin from a K5-TSLP mouse showing epidermal spongiosis (asterisk) and 
dermal infiltration by mast cells (arrows) and eosinophils (arrowheads) 
at 100 .
Figure 3. Immunohistochemical localizations of infiltrated mac-
rophages and Langerhans cells in the skin of a K5-TSLP mouse. As 
compared with the NLC, a larger number of macrophages and Langerhans 
cells (BM8 ) are infiltrated into affected skin areas of a K5-TSLP mouse.
 
Table I. 
 
Cytokine production by CD4
 
 
 
 T cells in K5-TSLP 
and control mice
 
Spleen PLN
 
a
 
MLN
 
Genotype
 
 
 
 
 
/4
 
 
 
 
 
 
 
/4
 
 
 
 
 
 
 
/4
 
 
 
 
 
 
 
/4
 
 
 
 
 
 
 
/4
 
 
 
 
 
 
 
/4
 
 
 
 
 
 
 
/4
 
 
 
 
 
 
 
/4
 
 
 
 
 
 
 
/4
 
 
 
NLC 2.09  3.18 1.70 0.15 0.82 0.07 0.24 3.46 0.02
NLC 3.44  1.23 1.51 0.68 0.40 0.05 0.62 1.35 0.09
K5-TSLP 1.43 40.94 0.64 1.45 6.14 0.20 1.75 10.17 0.41
K5-TSLP 0.94 60.26 0.78 2.60 15.17 0.58 1.89 11.87 0.41
K5-TSLP 1.34 46.96 0.90 3.41 4.08 0.31 0.78 7.26 0.07
 
After 5 wk of dox treatment, IFN-
 
 
 
 and IL-4 production by CD4
 
 
 
 T cells from the 
spleen, cutaneous peripheral LNs (PLN), and mesenteric LNs (MLN) of K5-TSLP and 
NLC mice were assessed by intracellular cytokine staining/flow cytometry after in 
vitro stimulation with PMA/ionomycin. Values shown are the percentage of CD4
 
 
 
 T 
cells producing the indicated combinations of IFN-
 
 
 
 and IL-4.
 
a
 
Inguinal LNs in K5-TSLP mice; pooled inguinal, axillary, brachial, and cervical LNs in NLC. 
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RT-PCR was performed to assess expression of cutaneous
chemokines in the skin of K5-TSLP and control mice (Fig. 5
B). Levels of CCL17 mRNA were dramatically increased in
the affected skin from K5-TSLP mice, whereas unaffected
skin also showed elevated levels and skin from control mice
had low but detectable levels (Fig. 5 B). We were unable to
detect expression of CCL22, the only other known CCR4
ligand, in any of the skin samples. Consistent with the expres-
sion of CCL17 in the skin and the Th2 phenotype of the
cells, CD4
 
 
 
 T cells in the spleens of K5-TSLP mice showed a
substantial increase in expression of CCR4, as assessed by
staining with a CCL22-Fc fusion protein (Fig. 5 C). CCR4
expression was correlated with a loss of the lymphoid tissue
homing receptors L-selectin and CCR7, indicating a shift in
the tropism of these pathogenic cells away from the secondary
lymphoid tissues and into the cutaneous lesions.
 
Skin inflammation in K5-TSLP mice is T cell independent
 
The data described in Figs. 4 and 5 demonstrate that CD4
 
 
 
T cells in the skin-draining LNs of K5-TSLP mice have a
pronounced Th2 phenotype. These data suggest a role for
CD4
 
 
 
 T cells in the development and/or progression of
skin inflammation in these mice. However, TSLP is thought
to directly activate DCs and other myeloid cells, and the ac-
cumulation of CD4
 
 
 
 Th2 cells may be a secondary effect of
TSLP overexpression that serves to amplify and sustain the
disease process. Therefore, to directly determine if Th2 cells
were required for disease in the K5-TSLP mice, these ani-
mals were crossed with mice lacking T cells (TCR
 
 
 
 
 
/
 
 
 
mice), resulting in K5-TSLP/T cell
 
 
 
/
 
 
 
 mice. K5-TSLP/T
cell
 
 
 
/
 
 
 
 mice, as well as controls, were given dietary dox for
3 wk, and skin inflammation was assessed histologically.
Epidermal thickening and dermal infiltration was observed
in the skin of both K5-TSLP and K5-TSLP/T cell
 
 
 
/
 
 
 
 mice
(Fig. 6, A–D). An examination of the cells contained in the
dermal infiltrates revealed mostly mast cells and eosinophils,
which was similar to what was seen in the TCR
 
 
 
 sufficient,
K5-TSLP mice (Fig. 6 E). In addition, the K5-TSLP/T
cell
 
 
 
/
 
 
 
 mice displayed little or no serum IgE, demonstrating
that T cells are necessary for the production of this isotype
and that B cells do not contribute greatly to the overall phe-
notype seen in these mice (unpublished data). These data
demonstrate that T cells are not required for the skin in-
flammation induced by TSLP, suggesting instead that this
cytokine acts directly on myeloid lineage cells to promote
atopic inflammation.
 
DISCUSSION
 
The current model for the pathogenesis of allergic diseases
holds that, after entry of allergen into the body, local DCs
process antigen and migrate to the draining LNs. There,
they prime naive allergen-specific CD4
 
 
 
 T cells, leading to
their differentiation into Th2 effector lymphocytes that se-
crete proallergic inflammatory cytokines, including IL-4,
IL-5, IL-13, and TNF-
 
 
 
. IL-4, in conjunction with cell
surface interactions, promotes class switch of allergen-spe-
cific B cells to IgE, resulting in mast cell activation,
whereas IL-5 promotes the differentiation and activation of
eosinophils. The degranulated products of mast cells and
Figure 4. The CD4  T cell response in K5-TSLP mice is Th2 cell 
polarized. (A) Intracellular proallergic cytokine staining of splenic CD4  
T cells isolated from a K5-TSLP mouse and an NLC after 5 wk of dox treatment. 
The percentages of cells in each quadrant are shown. Data are representative 
of more than five animals analyzed in this manner. (B) RT-PCR analysis of 
cytokine gene expression in the lesional skin of a K5-TSLP mouse and skin 
from an NLC.
 
Table II. 
 
Serum immunoglobulin levels in K5-TSLP 
and control mice
 
Genotype Dox
 
a
 
IgG
 
1
b
 
IgG
 
2a
b
 
IgE
 
b
 
mg/ml mg/ml mg/ml
 
K5-TSLP  3 339.8 41.6 50.5
NLC  3 191.2 176.6 n.d.
K5-TSLP  4 379.0 14.7 82.9
K5-TSLP  4 369.0 7.1 72.1
NLC  4 283.5 75.6 n.d.
K5-TSLP  5 143.8 14.6 54.3
NLC  5 71.5 148.0 n.d.
 
n.d., none detected.
 
a
 
Number of weeks of dietary dox treatment.
 
b
 
Measured by ELISA. 
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eosinophils then contribute directly to the clinical pheno-
type seen in atopic disease (5–7).
An essential step in this pathway is the activation of DCs
and their subsequent maturation into cells capable of priming
a Th2 effector T cell response. However, the factors that
promoted this maturation remained obscure until recently.
TSLP can activate CD11c
 
 
 
 DCs in vitro, and these DCs
subsequently promote differentiation of Th2 effector cells (9,
11), suggesting that this cytokine may function as one of the
initiating factors in allergic inflammation in vivo
 
.
 
 Consistent
with this hypothesis, TSLP is expressed in the affected skin
of AD patients, where it is associated with DC activation and
migration (11). We show that transgenic overexpression of
this cytokine in murine skin results in allergic inflammation
with the clinical, histologic, and immunologic characteristics
of human AD. This AD-like phenotype is accompanied by
massive lymphadenopathy and splenomegaly and a dramatic
increase in both the frequency and absolute number of IL-4–
producing Th2 CD4
 
 
 
 T cells. In a similar fashion, mice that
express a lung-specific TSLP transgene develop a spontane-
ous airway inflammatory disease resembling human asthma
(unpublished data). These data provide the first direct dem-
onstration that overexpression of this cytokine in vivo does
indeed result in tissue-specific allergic inflammation.
The precise function of TSLP in promoting allergic in-
flammation remains to be defined. Its unique ability to en-
able DCs to prime Th2 responses strongly suggests that this
is one mechanism by which TSLP causes the AD-like syn-
drome in the K5-TSLP mice. However, although most
strongly expressed by myeloid lineage cells and CD11c
 
 
 
DCs in humans (9), the specific 
 
 
 
 chain–like TSLP receptor
(TSLPR) is also expressed by a variety of T and B cell lines
(unpublished data; Rawlings, D.J, personal communication).
Indeed, TSLP was first identified as a factor produced by
thymic epithelium that could promote B cell differentiation
(18). In this regard, it is similar to the related cytokine IL-7,
and the functional TSLP receptor complex consists of a het-
erodimer of TSLPR and the IL-7 receptor 
 
 
 
 chain (10, 19).
It is therefore possible that a portion of the phenotype ob-
served in the K5-TSLP mice is a result of this cytokine act-
ing on CD4
 
 
 
 T cells, as recently shown by Al-Shami et al.
(20). However, the finding that K5-TSLP, TCR
 
 
 
 
 
/
 
 
 
 mice
still develop skin inflammation suggests that CD4
 
 
 
 T cells
are not required for disease development and progression
Figure 5. CD4  T cells in the K5-TSLP mice express cutaneous 
homing receptors. Flow cytometry analysis of homing receptor expression 
by CD4  T cells isolated from a K5-TSLP mouse and an NLC after 5 wk of dox 
treatment. Data are representative of more than five animals analyzed in 
this manner. (A) P-ligand (P-lig) and E-ligand (E-lig) expression was assessed 
by binding to P- and E-selectin–IgM fusion proteins in conjunction with 
intracellular cytokine staining to detect expression of IL-4. The percentages 
of cells in each quadrant are shown. Per., peripheral. (B) RT-PCR analysis of 
chemokine expression in the skin of a K5-TSLP mouse and NLC after 3 wk 
of dox treatment. From the K5-TSLP mouse, total RNA isolated from affected 
lesional skin (L) and unaffected skin (U) were analyzed separately. The levels 
of mRNA of CCL17, CCL22, and  -actin were determined by semiquantita-
tive RT-PCR analysis with threefold serial dilution of the template cDNA. 
(C) CCR4 and CCR7 expression assessed by binding to CCL22- and CCL19-
IgG3 fusion proteins in conjunction with staining for L-selectin (L-sel). The 
percentages of cells in each quadrant are shown. 
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and that TSLP may directly activate macrophages, eosino-
phils, mast cells, and other myeloid effector cells that medi-
ate allergic inflammation.
Epithelial overexpression of TSLP likely represents one
of the early events in allergic inflammation. The fact that
TSLP is not universally overexpressed in the skin of AD pa-
tients, but rather is limited to those areas manifesting disease,
implies that other local factors must play a role in triggering
TSLP overexpression on contact with allergen in affected in-
dividuals. Identifying these triggers is therefore essential for
understanding the etiology of allergic diseases such as AD. It
has long been recognized that genetic factors play a role in
susceptibility to AD and other allergic diseases. Therefore, it
will be of great interest to determine whether polymor-
phisms in the TSLP gene correlate with susceptibility to al-
lergic inflammation. However, as many other factors, such as
skin barrier disruption, 
 
Staphylococcus aureus
 
 colonization, and
various other immunologic abnormalities, have been linked
to AD, it seems likely that a genetic polymorphism in TSLP
would be one of many predisposing factors that act in con-
junction to induce a disease phenotype.
The adhesion molecules and chemoattractant receptors
that mediate leukocyte homing are responsible for recruiting
the necessary and appropriate cell types to sites of infection
and inflammation (21). Such molecules are differentially as-
sociated with specific cell types, tissues, and/or inflammatory
settings and are thus necessary for precisely correlating in-
flammatory cell function and tissue localization in any given
disease setting. As such, they also serve as important targets
for disease intervention. P- and E-selectin mediate homing
of CD4
 
 
 
 T cells into inflamed skin, and their expression is
rapidly up-regulated on vascular endothelial cells during cu-
taneous inflammation (22). Reciprocally, CD4
 
 
 
 T cells up-
regulate selectin ligands on activation in cutaneous lymphoid
tissues (23). In the dox-treated K5-TSLP mice, there is a
dramatic increase in the frequency of Th2 cells that coex-
press E- and/or P-ligand, which is consistent with the skin-
specific expression of TSLP in this model. Lymphocyte mi-
gration to the skin is also mediated by cutaneous chemokines
and their corresponding receptors. The K5-TSLP mice had
an elevated frequency of CD4
 
 
 
 T cells expressing the
chemokine receptor CCR4. CCR4 is associated with hom-
ing to sites of cutaneous inflammation (24, 25), and its ligand
CCL17 is expressed in the affected skin of AD patients and
in the K5-TSLP mice (26). In addition to its role in T cell
homing to the skin, CCR4 expression is strongly associated
with Th2 phenotype cells (16). Interestingly, human DCs
activated by TSLP produce the CCR4 ligands CCL17 and
CCL22 (11). In the secondary lymphoid tissues, this may set
up a positive feedback loop by attracting IL-4–producing
Th2 cells to TSLP-stimulated DCs, further promoting their
selective activation and expansion.
Th2 cytokine–mediated allergic reactions are orches-
trated in both innate and adaptive immune cells. Interest-
ingly, K5-TSLP, TCR
 
 
 
 
 
/
 
 
 
 mice show AD symptoms such
as thickening of the skin and cellular infiltrates, similar to
those seen in TCR
 
 
 
 K5-TSLP mice (Figs. 2 and 6). In ad-
dition, 
 
rag2
 
-deficient mice expressing a lung-specific TSLP
transgene still developed asthma-like symptoms (unpub-
lished data). Our data are consistent with a two-stage model
for TSLP-mediated inflammation. Initially, local production
of TSLP by epithelial cells leads to the stimulation and re-
cruitment of macrophages and eosinophils, resulting in the
cellular infiltrate seen in the K5-TSLP, TCR  /  mice. In
addition, skin-resident DCs, matured through exposure to
TSLP, migrate to the draining LNs and attract and activate
Th2 CD4  T cells. Thus, the initial targets of TSLP expres-
sion at sites of inflammation are likely myeloid-derived
cells, which are then capable of initiating the disease pro-
cess. Lymphoid cells are then involved in the progression
and amplification of the disease. Several lines of evidence
support this model. First, K5-TSLP mice lacking T cells still
develop skin-specific inflammatory disease, and rag2-defi-
cient mice expressing a lung-specific TSLP transgene de-
Figure 6. Histological observations of the skin in different geno-
types of mice that were crossed between K5-TSLP and TCR  KO 
mice. (A) A wild-type mouse without the transgene for K5-TSLP and KO 
alleles for TCR . (B) A mouse without the transgene for K5-TSLP but with 
KO alleles for TCR . (C) A mouse with the transgene for K5-TSLP but with-
out KO alleles for TCR . (D) A mouse with the transgene for K5-TSLP and 
KO alleles for TCR . Skin sections show pronounced acanthosis (asterisks) 
and infiltration in K5-TSLP mice with and without KO alleles for TCR  at 
10  (C and D), suggesting that skin symptoms of AD occur in K5-TSLP 
mice, regardless of whether    T cells are present. All paraffin-embedded 
sections were stained with H&E. (E) H&E-stained skin sections from 
K5-TSLP, TCR  /  and K5-TSLP, TCR  /  mice at 100 , showing the 
presence of eosinophils (closed arrowheads) and mast cells (open arrow-
heads) in skin from both sets of mice.JEM VOL. 202, August 15, 2005 547
ARTICLE
velop airway inflammation (Fig. 6 and not depicted). Sec-
ond, TSLP treatment of CD11c  DCs and bone marrow–
derived macrophages leads directly to Stat5 activation and
CCL17 production (unpublished data; Roach, S.K., per-
sonal communication), indicating that TSLP can directly
activate myeloid lineage cells. In addition, Osborn et al. (27)
showed that systemic TSLP transgene expression affected
myelopoiesis. Finally, eosinophils were capable of migrating
to the lung and producing IL-4 in rag2-deficient mice in-
fected with Nippostrongylus brasiliensis (28). Addition of anti-
gen-activated CD4  T cells led to eosinophil degranulation
at the site of inflammation, which was consistent with a sec-
ondary, amplifying role for T cells in the disease observed in
K5-TSLP mice.
The K5-TSLP mice present a novel model for AD, based
on the tissue-specific expression of a cytokine shown to be at
elevated levels in human patients. As TSLP is likely involved
in the initiating events of the inflammatory cascade, these
mice will allow for the dissection of downstream cells and
mediators that are critical for disease development and pro-
gression. The data presented here demonstrate that T cells
are not required for disease development. Future work will
focus on the role of inflammatory mediators, such as IL-4,
that have been implicated in the pathology of AD and other
allergic diseases (29). This inducible animal model of AD al-
lows for the identification and characterization of the various
aspects of AD pathogenesis from subclinical onset to final
disease phenotype and provides a preclinical model for the
analysis of new therapeutic modalities for the treatment of
this disease.
MATERIALS AND METHODS
Generation of inducible skin-specific TSLP transgenic mice (K5-
rtTA/tetO-TSLP). A cDNA encoding mouse TSLP was cloned into a
vector containing a heptameric tetracycline operator, CMV minimal pro-
moter, and rabbit  -globin intron (provided by D. Mathis, Harvard Medi-
cal School, Boston, MA). The tetO-TSLP insert was isolated and microin-
jected into [(C3H   C57BL/6F1)   C57BL/6] F2 oocytes. The offspring
were assessed for vector incorporation by PCR amplification of genomic
DNA processed from tail clippings using the following primers for the
TSLP cDNA: 5 -GACAGCATGGTTCTTCTCAG-3  and 5 -CTG-
GAGATTGCATGAAGG-3  (30 cycles of 94 C for 60 s denaturation,
55 C for 60 s annealing, and 72 C for 60 s extension). To generate tetracy-
cline-inducible skin-specific TSLP transgenic mice, tetO-TSLP mice were
crossed with K5-rtTA mice (provided by A. Glick, National Institutes of
Health, Bethesda, MD; reference 12). These latter mice contain the mouse
reverse tetracycline transactivator (rtTA) under the control of the keratin 5
(K5) promoter. Pups were screened for the presence of K5-rtTA using the
following primers: 5 -AGCTGCTTAATGAGGTCGGA-3  and 5 -GCT-
TGTCGTAATAATGGCGG-3  (30 cycles of 94 C for 60 s denaturation,
55 C for 60 s annealing, and 72 C for 60 s extension for both sets). After
weaning, mice containing both transgenes (referred to as K5-TSLP) were
treated with the tetracycline analogue dox at a concentration of 1 mg/ml in
the drinking water to induce rtTA transactivation of the TSLP transgene.
Nontransgenic and single-positive tetO-TSLP littermates were included as
controls. The TCR  KO mice were purchased from the Jackson Labora-
tory and crossed with K5-TSLP mice. The pups were screened using the
primers and conditions recommended by the vendor. All mice were main-
tained under specific pathogen-free conditions without manipulation and
were killed for analysis after 2.5–5 wk of dox treatment. All animal work
was conducted under conditions approved by the Benaroya Research Insti-
tute Animal Care and Use Committee.
Detection of TSLP expression. Total RNA was isolated from skin
samples using the RNeasy Mini Kit (QIAGEN). First strand cDNA was
synthesized from 1–2  g of total RNA using oligo(dT) priming and RT
(SuperScript II; Invitrogen). TSLP cDNA was PCR amplified from the re-
sulting first strand cDNA using the transgene-specific primers 5 -GACAG-
CATGGTTCTTCTCAG-3  and 5 -AGCCACCACCTTCTGATAGG-
3  (to distinguish from endogenous TSLP). The PCR reaction mixture was
run through 32 amplification cycles (94 C for 60 s denaturation, 55 C for
60 s annealing, and 72 C for 60 s extension), and the products were run on
1.5% agarose gel electrophoresis to detect TSLP mRNA expression. Prod-
ucts of PCR amplification using primers for  -actin (5 -GAGAGG-
GAAATCGTGCGTGA-3  and 5 -ACATCTGCTGGAAGGTGGAC-3 )
were included as controls.
Histopathology and immunohistochemistry. Skin sections were fixed
in 10% buffered formalin (VWR Scientific Products), embedded in paraffin,
and stained with H&E.
Antibodies and flow cytometry. Single cell suspensions were prepared
from the spleen, cutaneous peripheral LNs (cervical, axillary, and inguinal
nodes), and intestinal mesenteric LNs. For surface staining, the following
antibodies were used:  CD4-PerCP (clone RM4-5; BD Biosciences),
 CD8 –FITC (clone 53-6.7; eBioscience), and  CD62L-APC (clone
MEL-14; eBioscience). For intracellular cytokine staining, isolated splenic
or LN cells were activated in complete DMEM containing 50 ng/ml PMA,
1  g/ml ionomycin, and 10  g/ml monensin (all chemicals were obtained
from Sigma-Aldrich) for 4 h at 37 C and subsequently washed, surface
stained for expression of CD4 and CD8, fixed with 4% paraformaldehyde in
PBS, and permeabilized in Perm/Wash buffer (BD Biosciences). Cells were
then incubated for 30 min at 4 C with different combinations of the follow-
ing cytokine-specific mAbs (all were obtained from eBioscience) diluted in
Perm/Wash buffer:  IL-4–APC (clone 11B11),  IL-4–PE (clone 11B11),
 IFN- –FITC (clone XMG1.2),  IFN- –APC (clone XMG1.2),  IL-10–
PE (clone JES5-16E3), and  TNF- –PE (clone MP6-XT22). Labeled cells
were analyzed by flow cytometry. To assess binding of CD4  T cells to P-
and E-selectin (provided by J. Lowe, University of Michigan, Ann Arbor,
MI), cells were incubated sequentially with either a P- or E-selectin–human
IgM fusion protein (produced in COS-7 cells as previously described; refer-
ence 30), followed by biotinylated goat anti–human IgM (Jackson Immu-
noResearch Laboratories) and streptavidin–PE (eBioscience). After selectin–
ligand staining, cells were activated with PMA/ionomycin and stained for
expression of IL-4 as described above. CCL19– and CCL22–human IgG3
fusion proteins were used to examine expression of the chemokine recep-
tors CCR7 and CCR4, respectively. cDNAs encoding amino acids 26–108
of CCL19 and 25–92 of CCL22 were amplified from RNA isolated from
murine spleen and cloned in frame downstream of the human CD5 signal
sequence and upstream of the Fc portion of human IgG3 in the PEAK13
expression vector (provided by B. Seed, Harvard Medical School, Boston,
MA). These constructs were transiently transfected into COS-7 cells, and
the supernatants of these transfected cells were used directly to stain lym-
phocytes from the indicated mice. PE-labeled goat–anti–human IgG (Jack-
son ImmunoResearch Laboratories) was used to detect binding of the fu-
sion protein. As a specificity control, supernatants were preincubated for 5
min with blocking antibodies directed against either CCL19 (clone 87102;
R&D Systems) or CCL22 (clone 158132; R&D Systems), which com-
pletely abrogated staining.
Cutaneous cytokine and chemokine expression. Cytokine and che-
mokine expression in the skin was analyzed using RT-PCR. For IL-4, IL-5,
IL-13, TNF- , and IFN- , we used previously described primers and con-
ditions (31). For chemokine expression, the following primer sets were
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TCATGGCCTTGGGTTTTTCACC-3 ; CCL22, 5 -ATGGCTAC-
CCTGCGTGTCCCACTC-3  and 5 -CTAGGACAGTTTATGGAG-
TAGC-3 ; and CCL27, 5 -TGTTACTGTTGCTTCTGAGCCCG-3 
and 5 -GTTTTGCTGTTGGGGGTGTGAG-3 . PCR reactions were run
through 32–35 amplification cycles (94 C for 60 s denaturation, 55 C for
60 s annealing, and 72 C for 60 s extension), and products were separated
on 1.5% agarose gels to detect cytokine and chemokine mRNA expression.
Products of PCR amplification using primers for the housekeeping gene
glycerol-3-phosphate dehydrogenase (5 -GGTCATCCATGACAACTT-
TGG-3  and 5 -CATACCAGGAAATGAGCTTGAC-3 ) or  -actin (as
described in Detection of TSLP expression section) were included as
controls.
Measurement of serum immunoglobulin levels. Sera were analyzed
by ELISA for total IgG1, IgG2a, and IgE. For total serum IgG1 and IgG2a,
plates were coated overnight with 2  g/ml goat anti–mouse Ig (H L;
Southern Biotechnology Associates, Inc.), blocked with PBS/1% BSA, and
incubated sequentially with serial dilutions of mouse sera, 2  g/ml alkaline
phosphatase (AP)–conjugated rat anti–mouse IgG1/IgG2a (1:1,000; South-
ern Biotechnology Associates, Inc.), and 1 mg/ml of the AP substrate DNP
phosphate (DNPP; Sigma-Aldrich). For total serum IgE, plates were coated
with 2  g rat anti–mouse IgE (BD Biosciences), blocked with PBS/1%
BSA, and incubated sequentially with serial dilutions of mouse sera, biotin-
ylated rat anti–mouse IgE (1:1,000; BD Biosciences), SAV-AP (1:1,000;
BD Biosciences), and 1 mg/ml DNPP. All samples were analyzed in dupli-
cate or triplicate. Plates were read on a microplate autoreader (EL311S;
Bio-Tek Instruments, Inc.) at 405 nm, and concentrations were calculated
by plotting against standard curves generated from purified IgG1, IgG2a
(Southern Biotechnology Associates, Inc.), and IgE (BD Biosciences).
Online supplemental material. Fig. S1 shows the measurement of se-
rum IgE levels. Total IgE levels in serum were determined using ELISA, as
described in the previous section. Online supplemental material is available
at http://www.jem.org/cgi/content/full/jem.20041503/DC1.
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